ITMI911662A0 - Processo per la purificazione del virus dell'epatite a(hav) virus cosi' purificato e composizioni vaccinali che lo contengono - Google Patents

Processo per la purificazione del virus dell'epatite a(hav) virus cosi' purificato e composizioni vaccinali che lo contengono

Info

Publication number
ITMI911662A0
ITMI911662A0 IT91MI1662A ITMI911662A ITMI911662A0 IT MI911662 A0 ITMI911662 A0 IT MI911662A0 IT 91MI1662 A IT91MI1662 A IT 91MI1662A IT MI911662 A ITMI911662 A IT MI911662A IT MI911662 A0 ITMI911662 A0 IT MI911662A0
Authority
IT
Italy
Prior art keywords
hav
hepatitis
virus
purified
purification
Prior art date
Application number
IT91MI1662A
Other languages
English (en)
Inventor
Vittoria Pellegrini
Nicoletta Fineschi
J Arie Zuckerman
Original Assignee
Sclavo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sclavo Spa filed Critical Sclavo Spa
Publication of ITMI911662A0 publication Critical patent/ITMI911662A0/it
Priority to ITMI911662A priority Critical patent/IT1248075B/it
Priority to AT92109524T priority patent/ATE156187T1/de
Priority to ES92109524T priority patent/ES2104771T3/es
Priority to DK92109524.6T priority patent/DK0522291T3/da
Priority to EP92109524A priority patent/EP0522291B1/en
Priority to DE69221225T priority patent/DE69221225T2/de
Priority to JP4181643A priority patent/JPH07177882A/ja
Publication of ITMI911662A1 publication Critical patent/ITMI911662A1/it
Priority to US08/276,780 priority patent/US5607851A/en
Application granted granted Critical
Publication of IT1248075B publication Critical patent/IT1248075B/it
Priority to US08/457,310 priority patent/US5719049A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ITMI911662A 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. IT1248075B (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ITMI911662A IT1248075B (it) 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
EP92109524A EP0522291B1 (en) 1991-06-18 1992-06-05 Process for purifying hepatitis a virus (HAV), virus thus purified and vaccine compositions containing it
ES92109524T ES2104771T3 (es) 1991-06-18 1992-06-05 Procedimiento para purificar el virus de la hepatitis a (vha), el virus de dicha forma purificado y composiciones de vacunas que los contienen.
DK92109524.6T DK0522291T3 (da) 1991-06-18 1992-06-05 Fremgangsmåde til rensning af hepatitis A-virus (HAV), således renset virus og vaccinepræparater indeholdende dette
AT92109524T ATE156187T1 (de) 1991-06-18 1992-06-05 Verfahren zum reinigen von hepatits-a-virus (hav), so gereinigter virus und impfstoffzusammensetzungen, die ihn enthalten
DE69221225T DE69221225T2 (de) 1991-06-18 1992-06-05 Verfahren zum Reinigen von Hepatits-A-Virus (HAV), so gereinigter Virus und Impfstoffzusammensetzungen, die ihn enthalten
JP4181643A JPH07177882A (ja) 1991-06-18 1992-06-17 Ａ型肝炎ウイルス（ｈａｖ） の精製方法、こうして精製されたウイルス及びそれを含むワクチン組成物
US08/276,780 US5607851A (en) 1991-06-18 1994-07-18 Process for purifying hepatitis a virus (HAV), and vaccine compositions containing hepatitis a virus
US08/457,310 US5719049A (en) 1991-06-18 1995-06-01 Process for purifying hepatitis A virus (HAV), virus thus purified and vaccine compositions containing it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911662A IT1248075B (it) 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Publications (3)

Publication Number Publication Date
ITMI911662A0 true ITMI911662A0 (it) 1991-06-18
ITMI911662A1 ITMI911662A1 (it) 1992-12-18
IT1248075B IT1248075B (it) 1995-01-05

Family

ID=11360137

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI911662A IT1248075B (it) 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Country Status (8)

Country Link
US (2) US5607851A (it)
EP (1) EP0522291B1 (it)
JP (1) JPH07177882A (it)
AT (1) ATE156187T1 (it)
DE (1) DE69221225T2 (it)
DK (1) DK0522291T3 (it)
ES (1) ES2104771T3 (it)
IT (1) IT1248075B (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
AU732703B2 (en) * 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
DE69739961D1 (de) * 1996-12-13 2010-09-23 Schering Corp Methoden zur Virus-Reinigung
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP1815029A4 (en) * 2004-11-03 2009-06-10 Introgen Therapeutics Inc NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
CA2713891A1 (en) * 2008-02-12 2009-08-20 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
CN101816786B (zh) * 2010-04-30 2012-09-05 长春生物制品研究所有限责任公司 一种甲型肝炎灭活疫苗及其制备方法
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
JP6898535B1 (ja) * 2020-06-16 2021-07-07 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 アパタイトカラムを使用したウイルスの精製方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
JPS6147186A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
US4673634A (en) * 1985-03-08 1987-06-16 The United States Of America As Represented By The Department Of Health And Human Services Purified antigen from non-A, non-B hepatitis causing factor
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
EP0327801A1 (en) * 1988-01-08 1989-08-16 Deutsches Primatenzentrum Gesellschaft Mbh HIV-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン

Also Published As

Publication number Publication date
US5607851A (en) 1997-03-04
ITMI911662A1 (it) 1992-12-18
ATE156187T1 (de) 1997-08-15
EP0522291B1 (en) 1997-07-30
ES2104771T3 (es) 1997-10-16
DK0522291T3 (da) 1997-08-18
EP0522291A1 (en) 1993-01-13
DE69221225T2 (de) 1998-03-19
US5719049A (en) 1998-02-17
DE69221225D1 (de) 1997-09-04
JPH07177882A (ja) 1995-07-18
IT1248075B (it) 1995-01-05

Similar Documents

Publication Publication Date Title
ITMI911662A0 (it) Processo per la purificazione del virus dell'epatite a(hav) virus cosi' purificato e composizioni vaccinali che lo contengono
ITMI931522A0 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
DE69232919D1 (de) Verbindungen und Verfahren zur Inhibierung von HIV- und verwandten Viren
DE69405329T2 (de) Reinigung von 2-Methylglutaro- oder Adiponitril
DE69330238D1 (de) Verfahren zur Herstellung des Ectoproteins des Hepatitis-C-Virus
IT9021958A0 (it) Procedimento di purificazione dell'ammoniaca
FI102165B (fi) Menetelmä monityydyttymättömien alifaattisten yhdisteiden puhdistamise ksi
NO931246D0 (no) Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)
BR9305994A (pt) Processo de purificação de 6-Aminocapronitrila
DE69310997D1 (de) Prillverfahren
PT88420A (pt) Process for the preparation of pharmaceutical compositions containing 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-ethyluracil and a method for treating hepatitis virus infections by using said compositions
ITMI910319A1 (it) Processo di dealogenazione di 1, 3-diossolani
IT8621734A0 (it) Processo per la preparazione dell'alfa-n-[(ipoxatin-9-il)pentilossicarbonil-]arginina
IT9021495A0 (it) Processo per la depurazione di un monomero vinilaromatico
ITFI930260A0 (it) Processo per l'estrazione e purificazione dell'alfal-antitripsina (alfal-pi)dalla frazione iv-1 di cohn.
ITMI931033A1 (it) Processo per la preparazione di gemfibrozil
IT1270672B (it) Procedimento di preparazione di composizioni orali contenenti chinoloni
IT9021564A0 (it) Processo per la purificazione di beta-interferone umano ricombinante, beta-interferone cosi' purificato e composizioni farmaceutiche che lo contengono
ZA932271B (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
ITMI922377A1 (it) Procedimento per conferire stabilita' ai residui e ai bitumi
ITMI912612A1 (it) 5-nitro-1-metil-imidazolil-3-terbutil-2-idrossi- 5-metossi-fenil-carbinolo, processo per prepararlo e relative composizioni farmaceutiche
DE69227368D1 (de) Herstellung von hepatitis a virus
ATA901190A (de) Aufgereinigter ziliärer neurotropher faktor
ES1025475Y (es) "jeringa perfeccionada"

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970626